161581-99-3

Basic information

• Product Name: (4-BROMOPHENYL)(2-FLUORO-4-HYDROXYPHENYL) METHANONE
• Synonyms: (4-BROMOPHENYL)(2-FLUORO-4-HYDROXYPHENYL) METHANONE
• CAS NO: 161581-99-3
• Molecular Formula: C₁₃H₈BrFO₂
• Molecular Weight: 295.1
• Mol File: 161581-99-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 441.8°Cat760mmHg
• Flash Point: 221°C
• Appearance: /
• Density: 1.583g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.622
• Storage Temp.: 2-8°C
• PKA: 6.72±0.20(Predicted)
• CAS DataBase Reference: (4-BROMOPHENYL)(2-FLUORO-4-HYDROXYPHENYL) METHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: (4-BROMOPHENYL)(2-FLUORO-4-HYDROXYPHENYL) METHANONE(161581-99-3)
• EPA Substance Registry System: (4-BROMOPHENYL)(2-FLUORO-4-HYDROXYPHENYL) METHANONE(161581-99-3)

Safety Data

• Hazardous Substances Data: 161581-99-3(Hazardous Substances Data)

Usage

Preparation

Preparation by demethylation of 4?-bromo- 2-fluoro-4-methoxybenzophenone (SM) with 62% aqueous hydrobromic acid in acetic acid at 125°. SM was obtained by Friedel–Crafts acylation of m-fluoroanisole with p-bromobenzoyl chloride in nitrobenzene in the presence of aluminium chloride.

InChI:InChI=1/C13H8BrFO2/c14-9-3-1-8(2-4-9)13(17)11-6-5-10(16)7-12(11)15/h1-7,16H

Upstream product

• 456-49-5 1-fluoro-3-methoxybenzene 
• 586-75-4 4-chlorobenzoyl chloride 
• 161581-95-9 (4-bromo-phenyl)-(2-fluoro-4-methoxy-phenyl)-methanone 

Downstream Products

• 161582-11-2 [4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl]-(4-bromo-phenyl)-methanone 
• 189197-69-1 Ro 48-8071 

Relevant articles and documents

INDUCTION OF ESTROGEN RECEPTOR BETA BY CHOLESTEROL BIOSYNTHESIS INHIBITORS AND METHODS OF TREATMENT OF CANCER

Disclosed herein are methods and compositions related to the discovery that cholesterol inhibitors induce the anti-proliferative protein, estrogen receptor beta (ERβ), in both ERα- positive and ERα-negative breast cancer cell lines, including triple negat

Amino alkenyloxybenzene derivatives

A method of lowering cholesterol which comprises administering to a host requiring such treatment an effective amount of a compound of the formula STR1 wherein one of R1 and R2 is C1-7 -alkyl and the other is C1-7 -alkyl or C2-6 -alkenyl-methyl; L is C1-11 -alkylene or C2-11 -alkenylene optionally bonded to the phenyl group via an O atom or L is 1,4-phenylene; n is 0 or, when L contains an O atom, n is 0 or 1; Q is C1-7 -alkyl, C2-10 -alkenyl or a group of formula STR2 wherein R is H, halogen, CF3, CN or NO2 ; R3 and R4 are H, C1-4 -alkyl or halogen; and R5 is H or, when R is H, R5 is H or halogen; or a pharmaceutically acceptable acid addition salt thereof, as well as certain compounds of formula I, are described.